RG
XBI icon

Rathbones Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rathbones Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$654K Buy
5,123
+1,240
+32% +$155K ﹤0.01% 420
2025
Q4 		$473K Buy
+3,883
New +$445K ﹤0.01% 460

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rathbones Group's XBI Position: Q1 2026 in Review

Rathbones Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 32% in Q1 2026, buying an estimated $155K and bringing the position to 5,123 shares worth $654K. The position accounts for ﹤0.01% of the portfolio, ranked #420.

Rathbones Group first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Rathbones Group held 5,123 shares of State Street SPDR S&P Biotech ETF worth $654K as of Q1 2026.
  • Rathbones Group bought 1,240 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $155K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #420 holding.
  • Rathbones Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.